ADVERTISEMENT

Sotagliflozin’s HFpEF benefit confirmed by new analyses

Mitchel Zoler   |   Conference Report   |   24 May 2021
ADVERTISEMENT

FROM ACC 2021

It’s now official: The investigational sodium-glucose cotransporter (SGLT) 1/2 inhibitor sotagliflozin is the first agent clearly shown in a prespecified analysis of randomized trials to improve clinical outcomes in patients with heart failure with reduced ejection fraction (HFpEF).

Dr. Deepak L. Bhatt

Researchers who ran the SCORED...

          

March Challenge

Ends in 11d 14h
left
right

Topic Challenges

left
right